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Glanzmann Thrombasthenia (GT) is a genetic platelet dys-
function and a life threatening disease. Although it is a rare dis-
ease, it is the most common genetic platelet disorder. Symptoms 
and signs are mucosal and dermal petechia, recurring epistaxis 
and gastrointestinal (GI) bleeding and menorrhagia. Findings 
may be mild to life threatening in severity (1).
Ankaferd Blood Stopper (ABS) is a topical hemostatic 
agent of herbal origin which has recently become available 
for clinical use (2). It has been approved by the Turkish Re-
public Health Ministry for local use in bleeding due to super-
ficial skin and dental disease. In the literature, there is a vast 
number of case reports regarding the application of ABS in 
gastrointestinal bleeding after surgical and dental procedures, 
both clinically and experimentally (3,4).
In this case presentation, a patient with GT is reported in whom 
3 months of gastrointestinal bleeding refractory to all medical 
therapies was controlled within a short time of using oral ABS.
CASE PRESENTATION
A 29 year-old female patient was diagnosed with GT at 13 
years of age. She did not experience a significant bleeding epi-
sode requiring medical intervention except menorrhagia until 
she was 24 years-old, at which time she was admitted to our 
clinic. Her diagnosis was confirmed with a history of muco-
sal bleeding, the existence of GT in her sister, and prolonged 
collagen-ADP and collagen epinephrine assays with Platelet 
Function Analyzer (PFA-100; Dade Behring, Marbourg, Ger-
many). While her platelet counts were normal, the PFA and 
bleeding time were prolonged and no response was seen to all 
agonists except ristocetin by light transmission aggregometry 
(Chrono-log Whole-Blood Lumi-Aggregometer 560-CA with 
AGGRO/LINK® 5.1, Chrono-log Corp, Haverton, PA, USA). 
Surgical intervention for a diagnosis of endometriosis was 
performed with apheresis platelet suspension support, with-
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out complications at that time. There was only one episode 
of menorrhagia 4 years ago which was unresponsive to anti-
fibrinolytic and high dose progesterone treatment and apher-
esis platelet transfusions, and the menorrhagia was controlled 
with recombinant factor VIIa (rFVIIa). She was followed up 
for 4 years without any problem. Three months ago, she had 
taken non-steroidal anti-inflammatory drugs and was admit-
ted at a different medical center due to dark stools. The GI 
system bleeding had continued in spite of all interventions, 
including apheresis platelet suspension, octostim, and rFVIIa, 
and then she was referred to our institution. Upon admission, 
her hemoglobin level was 7.1 g/dL, and platelet count was 
320x109/L. Oral feeding was stopped; a proton pump inhibitor 
was given with the addition of daily apheresis platelet support. 
The origin of bleeding was not detected with GI endoscopic 
intervention. As the bleeding continued, supportive therapies 
such as tranexamic acid, vitamin K, and fresh frozen plasma 
were administered in addition to platelet and red blood cell 
replacements. Because the patient did not respond to any treat-
ments, she was given rFVIIa on the 38th, 45th, and 58th days at 
a dose of 90 µg/kg, 3 times with 2 hour intervals, but bleeding 
could not be stopped. She was given ABS by oral administra-
tion at a dose of 3x4 mL because the origin of the bleeding had 
not been determined and owing to a life threatening reduction 
in hemoglobin levels in contrast with support of red blood cell 
transfusion. She gave informed consent before administration 
of the drug. The hemoglobin levels stabilized on the 3rd day 
and the stool color began to return to normal on the 5th day. 
This treatment was continued for 10 days. The bleeding symp-
toms disappeared and hemoglobin levels returned to normal at 
the end of the 10th day, and the patient began to be followed 
without treatment (Figure 1). The patient was administered a 
total of 70 units of apheresis platelets and 82 units of eryth-
rocyte suspension during the 85 day process starting from the 
beginning of bleeding until the bleeding was controlled.
DISCUSSION
The bleeding episodes in GT are mostly mucosal bleeding, 
and the most frequent reasons for admittance to the hospital 
are gingival bleeding, epistaxis and serious menorrhagia (1). 
Unfortunately, treatment of patients with serious gastrointesti-
nal bleeding as a life-threatening bleed is difficult. Bakdash et 
al. (5) could not control the bleeding in a 48-year-old female 
patient with endoscopic intervention, HLA-matched platelet 
transfusions and rFVIIa, and reported controlling the bleeding 
with partial gastrectomy after platelet transfusions and rFVIIa 
support. Bhat et al. (6) used rFVIIa in their patient with GT 
when the patient was 4-years-old for an upper gastrointesti-
nal system bleed, and when the patient was 9-years-old for a 
lower GI system bleed; they reported improvement in bleed-
ing in their study following their experience with rFVIIa in 
life-threatening bleeds.
Ankaferd Blood Stopper is a mixture of a number of herbs, 
and its effects on endothelial cells, blood cells, angiogenesis, 
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FIG. 1. Hemoglobin levels during gastrointestinal bleeding and effect of Ankaferd Blood Stopper
The bleeding in the patient can be seen to have been ameliorated from the first day of hospitalization and the Hb levels are shown for a 90 day period. Straight arrows 
indicate the days where rFVIIa was administered, while dotted lines indicate the initiation of ABS. rFVIIa: recombinant factor VIIa; ABS: Ankaferd Blood Stopper
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cell proliferation, vascular dynamics and/or mediators were 
shown. Its hemostatic effect is independent from blood clotting 
factors and occurs as a result of the aggregation of red blood 
cells by an encapsulated protein web (2). It has been used in 
Turkey in many clinical cases of bleeding in which convention-
al measures were not sufficient for control of the episode.
The success of ABS in patients with a normal hemostatic 
system was mostly shown for gastrointestinal bleeds (3) and 
dental applications (4). All of these applications were local 
administrations, with a median ABS amount of between 1 mL 
and 20-30 mL.
As the patient presented in this paper has a hemostasis de-
fect, the medical literature on ABS applications in patients 
with a disorder of hemostasis was investigated, and more lim-
ited data were found. The activity of ABS was shown in 27 he-
mophilia A patients for the control of bleeding following tooth 
extraction (7) and in 4 patients with von Willebrand disease, 
chronic liver disease, and mitral valve replacement for the ces-
sation of localized bleeding following dental procedures (8). 
Furthermore, the successful local application of ABS has been 
reported for massive hematuria in a hemodialysis patient com-
plicated with disseminated intravascular coagulation (9), and 
upper gastrointestinal bleeding in a patient in whom a severe 
immune thrombocytopenia had developed (10).
In the first of several reports in the literature on its use in 
patients with GT is report of a 24-year-old patient in who un-
controllable tooth gum bleeding during periodontal treatment 
was controlled by the local use of ABS (11). In the others, 
the efficacy of ABS was shown in oral cavity bleeding in 2 
patients with GT, and in another 12 patients with hemophilia 
A or with other factor deficiencies (12).
In conclusion, ABS might be effective in patients with GT 
who have refractory GI bleeding. Another difference of this 
patient in comparison with other cases presented in the medi-
cal literature is the oral use of ABS. In only a few recent stud-
ies have high doses of oral ABS been reported to be safe in 
healthy rats (13) and tandem oral, rectal, and nasal adminis-
trations in patients with Klatskin tumor (14). Although this 
patient may contribute to the medical community in showing 
the safety and efficacy of systemic (oral) ABS in patients with 
disorders of hemostasis, it is obvious that further experience 
on its use in patients and further clinical studies are needed.
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